These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37445733)

  • 21. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma.
    Yang Z; Xu J; Li L; Li R; Wang Y; Tian Y; Guo W; Wang Z; Tan F; Ying J; Jiao Y; Gao S; Wang J; Gao Y; He J
    Nat Commun; 2020 Sep; 11(1):4878. PubMed ID: 32985499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
    Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
    Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunophenotyping of pulmonary sarcomatoid carcinoma.
    Ma Y; Li W; Li Z; Chen J; Wang H; Jiang T; Zhu J
    Front Immunol; 2022; 13():976739. PubMed ID: 36341325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.
    Tanaka I; Morise M
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
    Liu X; Wang F; Xu C; Chen X; Hou X; Li Q; Li P; Xie Z; Liu Y; Chang L; Guan Y; Zhang X; Yang L; Wang H; Yi X; Zhang J; Xia X; Moran C; Chen L
    Oncogene; 2021 Jan; 40(4):821-832. PubMed ID: 33273725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
    Reis H; Metzenmacher M; Goetz M; Savvidou N; Darwiche K; Aigner C; Herold T; Eberhardt WE; Skiba C; Hense J; Virchow I; Westerwick D; Bogner S; Ting S; Kasper S; Stuschke M; Nensa F; Herrmann K; Hager T; Schmid KW; Schuler M; Wiesweg M
    Clin Lung Cancer; 2018 Jul; 19(4):e441-e463. PubMed ID: 29631966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
    Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
    Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
    Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
    Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma.
    Chan K; Vong H; Chu W; Cheng K; Zhong X; Wen J
    Pol J Pathol; 2021; 72(3):222-228. PubMed ID: 35048634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
    Yang Z; Xu J; Li R; Gao Y; He J
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.
    Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.
    Xu L; Tao NN; Liang B; Li DW; Li HC; Su LL
    Thorac Cancer; 2022 Feb; 13(3):502-505. PubMed ID: 34953097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
    Luo Y; Wei J; Zhang J; Zeng L; Zeng Z; Liu A
    Lung Cancer; 2021 May; 155():170-174. PubMed ID: 33838468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.